Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Varian claims key role in Spanish IGRT installation

This article was originally published in Clinica

Executive Summary

Varian Medical Systems is claiming a major role in equipping the first hospital in northern Spain to offer state-of-the-art image-guided radiotherapy (IGRT), after installing three linacs, other equipment and related guidance systems at a new centre. Hospital General de Navarra, in the city of Pamplona, has installed Spain's second only Trilogy linac, "full accessorised" with its On-Board Imager guidance system, said the Palo Alto, California firm. It has also supplied two Clinac 21EX accelerators; an Acuity cone-beam CT, a full ARIA suite and Eclipse treatment planning software. Dr Anastasio Rubio Arroniz, chief of radiotherapy physics, said this represented a step-change in the region's capacity to provide IGRT, intensity-modulated (IMRT) and whole-body stereotactic radiosurgery (SRS) - the latter is to be offered in the near future, he said. The hospital serves a population of 600,000, including 1,200 cancer patients per year.

You may also be interested in...



Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Dr Reddy’s Knocked Back On Rituximab In US

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Sandoz And Samsung Celebrate Stelara Rival’s EU Approval

Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel